Schwaiger M, Egert S, Brosius F
Nuklearmedizinische Klinik und Poliklinik, TU München Klinikum rechts der Isar.
Z Kardiol. 1995;84 Suppl 4:115-23.
Identification of viable myocardium in patients with impaired left ventricular function, who are possible candidates for revascularization, represents an important clinical question. Modern methods of revascularization provide a therapeutic alternative to conventional pharmacological therapy even in patients with advanced ischemic heart disease. Modern diagnostic techniques make it possible to assess not only the extent of ischemia under exercise conditions, but also the presence of viable tissue in patients with severe coronary artery disease and impaired ventricular function. Currently, the most accurate methods for scintigraphic quantification of viable myocardial tissue are metabolic investigations with positron emission tomography (PET). Because of the limited availability of PET other methods like thallium-201-scintigraphy play an important clinical role. Modifications of thallium-201-scintigraphy, for example the introduction of reinjection protocols have improved the recognition of viable tissue and decreased the diagnostic difference to PET. We recommend as standard diagnostic procedure for assessment of tissue viability thallium-201-scintigraphy with reinjection. In patients with severely depressed left ventricular function and equivocal thallium-201-scintigraphy findings, PET should be considered as further diagnostic test. Low dose dobutamine-echocardiography is emerging as alternative test for evaluation of contractile reserve in dysfunctioning left ventricular segments. Its clinical role, however, remains to be determined. Besides the clinical application of these methods, newly developed radiotracers, together with PET, may provide insights into the mechanism of metabolic adaptations in patients with repeated episodes of ischemia. Furthermore, correlation of clinical data with in vitro histological and biological tissue analysis in the same patients may provide a better understanding of metabolic alterations observed in chronic ischemic heart disease.
对于左心室功能受损且可能适合血运重建的患者,识别存活心肌是一个重要的临床问题。即使是患有晚期缺血性心脏病的患者,现代血运重建方法也为传统药物治疗提供了一种治疗选择。现代诊断技术不仅能够评估运动状态下的缺血程度,还能评估严重冠状动脉疾病和心室功能受损患者体内存活组织的存在情况。目前,用于存活心肌组织闪烁显像定量分析的最准确方法是正电子发射断层扫描(PET)代谢研究。由于PET的可用性有限,其他方法如铊-201闪烁显像发挥着重要的临床作用。铊-201闪烁显像的改进,例如引入再注射方案,提高了对存活组织的识别能力,并减少了与PET的诊断差异。我们建议将铊-201再注射闪烁显像作为评估组织活力的标准诊断程序。对于左心室功能严重降低且铊-201闪烁显像结果不明确的患者,应考虑将PET作为进一步的诊断检查。低剂量多巴酚丁胺超声心动图正逐渐成为评估左心室功能不全节段收缩储备的替代检查方法。然而,其临床作用仍有待确定。除了这些方法的临床应用外,新开发的放射性示踪剂与PET一起,可能有助于深入了解反复缺血患者的代谢适应机制。此外,将同一患者的临床数据与体外组织学和生物学组织分析相关联,可能有助于更好地理解慢性缺血性心脏病中观察到的代谢改变。